Xuming Zhusan Decoction Attenuates Post‐Stroke via Modulating TLR4/MYD88/NF‐κB Pathway in Mice

分享:

简介:

  • 作者: Xi Liu, Cheng Wang, Ling Han, Yi'an Xiao, Hanchang Yu, Zhongxu Hu, Xiyun Fei, Min Peng, Jilin Zhou, Zhijun Zhong
  • 杂志: Food Science & Nutrition
  • Doi: https://www.doi.org/10.1002/fsn3.71734
  • 出版日期: 2026/4/16

论文中使用的产品/服务

询价

摘要

Ischemic stroke induces neuroinflammation that exacerbates neuronal damage. The Chinese Medicine Xuming Zhusan (XMZS) has shown promising efficacy in stroke treatment, but its mechanisms are unclear. This study aimed to explore the effect of XMZS on microglial‐mediated neuroinflammation and explore its molecular targets. In vivo experiments were conducted using a mouse model of cerebral ischemia–reperfusion injury induced by middle cerebral artery occlusion (MCAO), and in vitro studies were performed on primary microglia and cortical neurons with Oxygen–Glucose Deprivation/Reoxygenation (OGD/R) models. Behavioral assessments, histological analyses, Western blotting, co‐immunoprecipitation, confocal microscopy, and enzyme‐linked immunosorbent assay (ELISA) were employed to evaluate the neuroprotective effects of XMZS and its regulatory role in the TLR4/MYD88/NF‐κB pathway. Results showed that high‐dose (63 g/kg) XMZS improved neurological and cognitive functions, reduced infarct volume and brain edema in MCAO mice. Mechanistically, XMZS suppressed microglial activation, decreased the levels of pro‐inflammatory cytokines (IL‐1β, IL‐6, TNF‐α), and downregulated the expression of TLR4, MYD88, and phosphorylated p65 in the TLR4/MYD88/NF‐κB pathway. Additionally, cinditioned medium from XMZS‐treated microglia enhanced the viability of primary neurons. In conclusion, XMZS exerts neuroprotective effects against cerebral ischemia–reperfusion injury by modulating the TLR4/MYD88/NF‐κB pathway, thereby attenuating microglia‐mediated neuroinflammation.

关于派真

作为一家专注于AAV 技术十余年,深耕基因治疗领域的CRO&CDMO,派真生物可提供从载体设计、构建到 AAV、慢病毒和 mRNA 服务的一站式解决方案。凭借深厚的技术实力、卓越的运营管理和高标准的服务交付,我们为全球客户提供一站式CMC解决方案,包括从早期概念验证、成药性评估到IITINDBLA的各个阶段。

 

凭借我们独立知识产权的π-alphaTM 293 细胞AAV高产技术平台,我们能将AAV产量提高多至10倍,每批次产量可达1×10¹⁷vg,以满足多样化的商业化和临床项目需求。此外,我们定制化的mRNA和脂质纳米颗粒(LNP)产品及服务覆盖药物和疫苗开发的各个阶段,从研发到符合GMP的生产,提供端到端的一站式解决方案。

下载

用户登录

还没账号? 请注册
手机验证码登录
账号密码登录
手机号码*
验证码*
忘记密码?

首次使用手机号登录将自动为您注册

登录即代表阅读并接受《注册协议》 《用户协议》

新用户注册

已有账号?
手机注册
邮箱注册
手机号码*
验证码*
机构名称*
客户类型*

重置密码

手机找回密码
邮箱找回密码
手机号码*
验证码*
设置新密码*
确认新密码*